Global and China Typhoid Vaccine research

Typhoid Vaccine Comprehensive Study by Type (Oral, Injection), Application (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - Global Market Outlook to 2024

Typhoid Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Typhoid Vaccine Market Overview:
Typhoid vaccine contains a suspension of inactivated Salmonella typhi which is used to immunize against typhoid fever. This helps to protect against typhoid disease, an infection caused by typhoid bacteria. The typhoid vaccine is highly recommended for people who travel to high-risk areas.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Market Growth Drivers:
Rising Prevalence of Typhoid, Growing Immunization Campaign and Increase in Government Initiatives in Various Countries

Challenges:
Inadequate Preclinical Data And Lack Of Detailed Information On Protective Correlates Of Immunity Contribute To Product Failure In Clinical Trials

Restraints:
High Cost Associated With Vaccine Development, Stringent Government Rules and Regulations and Less Availability to Vaccine in Remote Areas

Opportunities:
High Potential Growth in Emerging Market and Research and Development on Typhoid Vaccine in Emerging Market

Competitive Landscape:

Some of the key players profiled in the report are Sanofi (France), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), PaxVax (United States), Actiza Pharmaceutical (India), Merit Pharmaceuticals (India) and Bharat Biotec (India). Analyst at AMA Research see United States Players to retain maximum share of Global Typhoid Vaccine market by 2027.

What Can be Explored with the Typhoid Vaccine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Typhoid Vaccine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Typhoid Vaccine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Typhoid Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Typhoid Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Oral
  • Injection
By Application
  • Hospital
  • Research & Academic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Typhoid
      • 3.2.2. Growing Immunization Campaign
      • 3.2.3. Increase in Government Initiatives in Various Countries
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Preclinical Data And Lack Of Detailed Information On Protective Correlates Of Immunity Contribute To Product Failure In Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Typhoid Vaccine, by Type, Application and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Typhoid Vaccine (Value)
      • 5.2.1. Global Typhoid Vaccine by: Type (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Injection
      • 5.2.2. Global Typhoid Vaccine by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Research & Academic Laboratories
        • 5.2.2.3. Pharmaceutical & Biotechnology Companies
        • 5.2.2.4. Others
      • 5.2.3. Global Typhoid Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Typhoid Vaccine (Volume)
      • 5.3.1. Global Typhoid Vaccine by: Type (Volume)
        • 5.3.1.1. Oral
        • 5.3.1.2. Injection
      • 5.3.2. Global Typhoid Vaccine by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Research & Academic Laboratories
        • 5.3.2.3. Pharmaceutical & Biotechnology Companies
        • 5.3.2.4. Others
      • 5.3.3. Global Typhoid Vaccine Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Typhoid Vaccine (Price)
      • 5.4.1. Global Typhoid Vaccine by: Type (Price)
  • 6. Typhoid Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PaxVax (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Actiza Pharmaceutical (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merit Pharmaceuticals (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bharat Biotec (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Typhoid Vaccine Sale, by Type, Application and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Typhoid Vaccine (Value)
      • 7.2.1. Global Typhoid Vaccine by: Type (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Injection
      • 7.2.2. Global Typhoid Vaccine by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Research & Academic Laboratories
        • 7.2.2.3. Pharmaceutical & Biotechnology Companies
        • 7.2.2.4. Others
      • 7.2.3. Global Typhoid Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Typhoid Vaccine (Volume)
      • 7.3.1. Global Typhoid Vaccine by: Type (Volume)
        • 7.3.1.1. Oral
        • 7.3.1.2. Injection
      • 7.3.2. Global Typhoid Vaccine by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Research & Academic Laboratories
        • 7.3.2.3. Pharmaceutical & Biotechnology Companies
        • 7.3.2.4. Others
      • 7.3.3. Global Typhoid Vaccine Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Typhoid Vaccine (Price)
      • 7.4.1. Global Typhoid Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Typhoid Vaccine: by Type(USD Million)
  • Table 2. Typhoid Vaccine Oral , by Region USD Million (2016-2021)
  • Table 3. Typhoid Vaccine Injection , by Region USD Million (2016-2021)
  • Table 4. Typhoid Vaccine: by Application(USD Million)
  • Table 5. Typhoid Vaccine Hospital , by Region USD Million (2016-2021)
  • Table 6. Typhoid Vaccine Research & Academic Laboratories , by Region USD Million (2016-2021)
  • Table 7. Typhoid Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2016-2021)
  • Table 8. Typhoid Vaccine Others , by Region USD Million (2016-2021)
  • Table 9. South America Typhoid Vaccine, by Country USD Million (2016-2021)
  • Table 10. South America Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 11. South America Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 12. Brazil Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 13. Brazil Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 14. Argentina Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 15. Argentina Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 16. Rest of South America Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 17. Rest of South America Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 18. Asia Pacific Typhoid Vaccine, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 20. Asia Pacific Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 21. China Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 22. China Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 23. Japan Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 24. Japan Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 25. India Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 26. India Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 27. South Korea Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 28. South Korea Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 29. Taiwan Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 30. Taiwan Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 31. Australia Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 32. Australia Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 33. Rest of Asia-Pacific Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 34. Rest of Asia-Pacific Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 35. Europe Typhoid Vaccine, by Country USD Million (2016-2021)
  • Table 36. Europe Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 37. Europe Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 38. Germany Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 39. Germany Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 40. France Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 41. France Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 42. Italy Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 43. Italy Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 44. United Kingdom Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 45. United Kingdom Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 46. Netherlands Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 47. Netherlands Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 48. Rest of Europe Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 49. Rest of Europe Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 50. MEA Typhoid Vaccine, by Country USD Million (2016-2021)
  • Table 51. MEA Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 52. MEA Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 53. Middle East Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 54. Middle East Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 55. Africa Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 56. Africa Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 57. North America Typhoid Vaccine, by Country USD Million (2016-2021)
  • Table 58. North America Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 59. North America Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 60. United States Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 61. United States Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 62. Canada Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 63. Canada Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 64. Mexico Typhoid Vaccine, by Type USD Million (2016-2021)
  • Table 65. Mexico Typhoid Vaccine, by Application USD Million (2016-2021)
  • Table 66. Typhoid Vaccine Sales: by Type(K Unit)
  • Table 67. Typhoid Vaccine Sales Oral , by Region K Unit (2016-2021)
  • Table 68. Typhoid Vaccine Sales Injection , by Region K Unit (2016-2021)
  • Table 69. Typhoid Vaccine Sales: by Application(K Unit)
  • Table 70. Typhoid Vaccine Sales Hospital , by Region K Unit (2016-2021)
  • Table 71. Typhoid Vaccine Sales Research & Academic Laboratories , by Region K Unit (2016-2021)
  • Table 72. Typhoid Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Unit (2016-2021)
  • Table 73. Typhoid Vaccine Sales Others , by Region K Unit (2016-2021)
  • Table 74. South America Typhoid Vaccine Sales, by Country K Unit (2016-2021)
  • Table 75. South America Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 76. South America Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 77. Brazil Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 78. Brazil Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 79. Argentina Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 80. Argentina Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 81. Rest of South America Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 82. Rest of South America Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 83. Asia Pacific Typhoid Vaccine Sales, by Country K Unit (2016-2021)
  • Table 84. Asia Pacific Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 85. Asia Pacific Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 86. China Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 87. China Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 88. Japan Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 89. Japan Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 90. India Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 91. India Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 92. South Korea Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 93. South Korea Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 94. Taiwan Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 95. Taiwan Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 96. Australia Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 97. Australia Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 98. Rest of Asia-Pacific Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 99. Rest of Asia-Pacific Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 100. Europe Typhoid Vaccine Sales, by Country K Unit (2016-2021)
  • Table 101. Europe Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 102. Europe Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 103. Germany Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 104. Germany Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 105. France Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 106. France Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 107. Italy Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 108. Italy Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 109. United Kingdom Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 110. United Kingdom Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 111. Netherlands Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 112. Netherlands Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 113. Rest of Europe Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 114. Rest of Europe Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 115. MEA Typhoid Vaccine Sales, by Country K Unit (2016-2021)
  • Table 116. MEA Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 117. MEA Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 118. Middle East Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 119. Middle East Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 120. Africa Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 121. Africa Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 122. North America Typhoid Vaccine Sales, by Country K Unit (2016-2021)
  • Table 123. North America Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 124. North America Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 125. United States Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 126. United States Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 127. Canada Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 128. Canada Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 129. Mexico Typhoid Vaccine Sales, by Type K Unit (2016-2021)
  • Table 130. Mexico Typhoid Vaccine Sales, by Application K Unit (2016-2021)
  • Table 131. Typhoid Vaccine: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Typhoid Vaccine: by Type(USD Million)
  • Table 140. Typhoid Vaccine Oral , by Region USD Million (2022-2027)
  • Table 141. Typhoid Vaccine Injection , by Region USD Million (2022-2027)
  • Table 142. Typhoid Vaccine: by Application(USD Million)
  • Table 143. Typhoid Vaccine Hospital , by Region USD Million (2022-2027)
  • Table 144. Typhoid Vaccine Research & Academic Laboratories , by Region USD Million (2022-2027)
  • Table 145. Typhoid Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2022-2027)
  • Table 146. Typhoid Vaccine Others , by Region USD Million (2022-2027)
  • Table 147. South America Typhoid Vaccine, by Country USD Million (2022-2027)
  • Table 148. South America Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 149. South America Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 150. Brazil Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 151. Brazil Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 152. Argentina Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 153. Argentina Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 154. Rest of South America Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 155. Rest of South America Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 156. Asia Pacific Typhoid Vaccine, by Country USD Million (2022-2027)
  • Table 157. Asia Pacific Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 158. Asia Pacific Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 159. China Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 160. China Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 161. Japan Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 162. Japan Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 163. India Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 164. India Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 165. South Korea Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 166. South Korea Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 167. Taiwan Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 168. Taiwan Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 169. Australia Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 170. Australia Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 171. Rest of Asia-Pacific Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 172. Rest of Asia-Pacific Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 173. Europe Typhoid Vaccine, by Country USD Million (2022-2027)
  • Table 174. Europe Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 175. Europe Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 176. Germany Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 177. Germany Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 178. France Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 179. France Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 180. Italy Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 181. Italy Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 182. United Kingdom Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 183. United Kingdom Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 184. Netherlands Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 185. Netherlands Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 186. Rest of Europe Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 187. Rest of Europe Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 188. MEA Typhoid Vaccine, by Country USD Million (2022-2027)
  • Table 189. MEA Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 190. MEA Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 191. Middle East Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 192. Middle East Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 193. Africa Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 194. Africa Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 195. North America Typhoid Vaccine, by Country USD Million (2022-2027)
  • Table 196. North America Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 197. North America Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 198. United States Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 199. United States Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 200. Canada Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 201. Canada Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 202. Mexico Typhoid Vaccine, by Type USD Million (2022-2027)
  • Table 203. Mexico Typhoid Vaccine, by Application USD Million (2022-2027)
  • Table 204. Typhoid Vaccine Sales: by Type(K Unit)
  • Table 205. Typhoid Vaccine Sales Oral , by Region K Unit (2022-2027)
  • Table 206. Typhoid Vaccine Sales Injection , by Region K Unit (2022-2027)
  • Table 207. Typhoid Vaccine Sales: by Application(K Unit)
  • Table 208. Typhoid Vaccine Sales Hospital , by Region K Unit (2022-2027)
  • Table 209. Typhoid Vaccine Sales Research & Academic Laboratories , by Region K Unit (2022-2027)
  • Table 210. Typhoid Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Unit (2022-2027)
  • Table 211. Typhoid Vaccine Sales Others , by Region K Unit (2022-2027)
  • Table 212. South America Typhoid Vaccine Sales, by Country K Unit (2022-2027)
  • Table 213. South America Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 214. South America Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 215. Brazil Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 216. Brazil Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 217. Argentina Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 218. Argentina Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 219. Rest of South America Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 220. Rest of South America Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 221. Asia Pacific Typhoid Vaccine Sales, by Country K Unit (2022-2027)
  • Table 222. Asia Pacific Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 223. Asia Pacific Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 224. China Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 225. China Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 226. Japan Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 227. Japan Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 228. India Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 229. India Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 230. South Korea Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 231. South Korea Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 232. Taiwan Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 233. Taiwan Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 234. Australia Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 235. Australia Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 236. Rest of Asia-Pacific Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 237. Rest of Asia-Pacific Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 238. Europe Typhoid Vaccine Sales, by Country K Unit (2022-2027)
  • Table 239. Europe Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 240. Europe Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 241. Germany Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 242. Germany Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 243. France Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 244. France Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 245. Italy Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 246. Italy Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 247. United Kingdom Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 248. United Kingdom Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 249. Netherlands Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 250. Netherlands Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 251. Rest of Europe Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 252. Rest of Europe Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 253. MEA Typhoid Vaccine Sales, by Country K Unit (2022-2027)
  • Table 254. MEA Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 255. MEA Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 256. Middle East Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 257. Middle East Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 258. Africa Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 259. Africa Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 260. North America Typhoid Vaccine Sales, by Country K Unit (2022-2027)
  • Table 261. North America Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 262. North America Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 263. United States Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 264. United States Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 265. Canada Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 266. Canada Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 267. Mexico Typhoid Vaccine Sales, by Type K Unit (2022-2027)
  • Table 268. Mexico Typhoid Vaccine Sales, by Application K Unit (2022-2027)
  • Table 269. Typhoid Vaccine: by Type(USD/Units)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Typhoid Vaccine: by Type USD Million (2016-2021)
  • Figure 5. Global Typhoid Vaccine: by Application USD Million (2016-2021)
  • Figure 6. South America Typhoid Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Typhoid Vaccine Share (%), by Country
  • Figure 8. Europe Typhoid Vaccine Share (%), by Country
  • Figure 9. MEA Typhoid Vaccine Share (%), by Country
  • Figure 10. North America Typhoid Vaccine Share (%), by Country
  • Figure 11. Global Typhoid Vaccine: by Type K Unit (2016-2021)
  • Figure 12. Global Typhoid Vaccine: by Application K Unit (2016-2021)
  • Figure 13. South America Typhoid Vaccine Share (%), by Country
  • Figure 14. Asia Pacific Typhoid Vaccine Share (%), by Country
  • Figure 15. Europe Typhoid Vaccine Share (%), by Country
  • Figure 16. MEA Typhoid Vaccine Share (%), by Country
  • Figure 17. North America Typhoid Vaccine Share (%), by Country
  • Figure 18. Global Typhoid Vaccine: by Type USD/Units (2016-2021)
  • Figure 19. Global Typhoid Vaccine share by Players 2021 (%)
  • Figure 20. Global Typhoid Vaccine share by Players (Top 3) 2021(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2021
  • Figure 24. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co. (United States) Revenue: by Geography 2021
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 28. PaxVax (United States) Revenue, Net Income and Gross profit
  • Figure 29. PaxVax (United States) Revenue: by Geography 2021
  • Figure 30. Actiza Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 31. Actiza Pharmaceutical (India) Revenue: by Geography 2021
  • Figure 32. Merit Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 33. Merit Pharmaceuticals (India) Revenue: by Geography 2021
  • Figure 34. Bharat Biotec (India) Revenue, Net Income and Gross profit
  • Figure 35. Bharat Biotec (India) Revenue: by Geography 2021
  • Figure 36. Global Typhoid Vaccine: by Type USD Million (2022-2027)
  • Figure 37. Global Typhoid Vaccine: by Application USD Million (2022-2027)
  • Figure 38. South America Typhoid Vaccine Share (%), by Country
  • Figure 39. Asia Pacific Typhoid Vaccine Share (%), by Country
  • Figure 40. Europe Typhoid Vaccine Share (%), by Country
  • Figure 41. MEA Typhoid Vaccine Share (%), by Country
  • Figure 42. North America Typhoid Vaccine Share (%), by Country
  • Figure 43. Global Typhoid Vaccine: by Type K Unit (2022-2027)
  • Figure 44. Global Typhoid Vaccine: by Application K Unit (2022-2027)
  • Figure 45. South America Typhoid Vaccine Share (%), by Country
  • Figure 46. Asia Pacific Typhoid Vaccine Share (%), by Country
  • Figure 47. Europe Typhoid Vaccine Share (%), by Country
  • Figure 48. MEA Typhoid Vaccine Share (%), by Country
  • Figure 49. North America Typhoid Vaccine Share (%), by Country
  • Figure 50. Global Typhoid Vaccine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • Merck & Co. (United States)
  • GlaxoSmithKline (United Kingdom)
  • PaxVax (United States)
  • Actiza Pharmaceutical (India)
  • Merit Pharmaceuticals (India)
  • Bharat Biotec (India)
Select User Access Type

Key Highlights of Report


Nov 2019 211 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and China Typhoid Vaccine research Quantitative research analysis
Global and China Typhoid Vaccine research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Typhoid Vaccine market are Sanofi (France), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), PaxVax (United States), Actiza Pharmaceutical (India), Merit Pharmaceuticals (India) and Bharat Biotec (India), to name a few.
"" is seen as one of major influencing trends for Typhoid Vaccine Market during projected period 2021-2027.
Oral segment in Global market to hold robust market share owing to "Rising Prevalence of Typhoid ".

Know More About Global and China Typhoid Vaccine research Report?

Have a Query? Click Here

Other Related Reports

Clostridium Difficile Treatment Comprehensive Study by Type (Narrow Spectrum Antibiotics, Broad Spectrum Antibiotics), Route of Administration (Oral, Intravenous / Parenteral), Distribution Channel (...
$ 3750
Clinical Trial Packaging Comprehensive Study by Packaging (Syringes, Vials & Ampoules, Bottles, Bags & Pouches, Tubes, Sachets, Kits or Packs, Others), End-User (Research Laboratories, Clinical Resea...
$ 3500
Omeprazole Comprehensive Study by Type (Capsule, Powder, Tablet, Suspension), Application (Gastroesophageal Reflux Disease (GERD), Barrett's Oesophagus, Duodenal Ulcer, Erosive Esophagitis, Hiatal He...
$ 3750
Primary Biliary Cirrhosis Drug Comprehensive Study by Type (Budesonide, FFP-104, GSK-2330672, MBX-8025, NGM-282, Others), Application (Clinic, Hospital, Others), Tests (Computed Tomography (CT), Ultr...
$ 3450
Cosmeceuticals Comprehensive Study by Type (Cleansing Agents, Mineral Oils, Herbal extract, Surfactants, Emollients, Enzymes, Others), Application (Skin Care, Hair Care, Oral Care, Eye Care, Others),...
$ 3650
Absorbent Dressing Comprehensive Study by Type (Traditional Wound Dressings, Advanced Wound Dressings), Application (Surgical Wounds, Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers, Burns, Othe...
$ 3350